Hims & Hers (HIMS) Drops ~18% as Q3 Gross Margin Craters on the GLP-1 Shift

Why Hims & Hers stock dropped — Q3 growth masked a gross-margin squeeze

On Tuesday, November 10, 2026, Hims & Hers Health (NYSE: HIMS) fell about 18%, trading near $18.76 intraday — a seven-month low — after the telehealth company's third-quarter results, released the evening before, landed badly [1]. The paradox is that the top line was strong: revenue rose 49% to about $890 million. The problem was underneath it. Gross margin collapsed to about 57%, from 74% a year earlier, the company swung to a $33 million net loss (about $0.14 a share, versus a small profit expected and a profit a year ago), and it cut its full-year profit guidance [2]. Fast growth that destroys margins is exactly what a market does not want to see, and it sold the stock hard.

The culprit is the same thing that made HIMS a market darling in the first place: weight-loss drugs. Hims built an explosive growth engine partly by offering GLP-1 medications, and as the era of cheap compounded versions wound down, it pivoted to selling branded weight-loss drugs. Branded drugs are a low-margin, pass-through business: HIMS buys them and resells them, keeping far less of each dollar than it earns on its high-margin subscription services or on the compounded drugs it used to sell. On the earnings call, management said the quarter's margin drop came principally from scaling these lower-margin branded weight-loss products, especially in its fast-growing international business [2]. (A separate, just-announced deal to distribute Eli Lilly's branded Zepbound — unveiled on November 6, after the quarter closed — had lifted the stock about 8% the prior Friday, but it postdates these results and did not cause them.) So the GLP-1 mix shift that keeps revenue growing is simultaneously compressing margins — the central tension this quarter laid bare [2].

What actually spooked investors — margins, subscribers and a guidance cut

Three things drove the sell-off, and none was the revenue line. First, the margin collapse: gross margin has slid all year — about 74%, then 72%, 64% and now 57% — and the 17-point year-over-year drop pushed the company to a GAAP net loss. (Notably, its adjusted EBITDA stayed positive and even edged higher, about $82 million versus $78 million a year earlier, so the deterioration showed up in the margin and in GAAP profitability, not in adjusted operating profit, which stayed positive) [2]. Second, subscribers disappointed: Hims ended the quarter with about 2.79 million subscribers, up 13% from a year ago but below the roughly 3.04 million analysts expected and down about 100,000 from the prior quarter — a sequential decline the company blamed partly on pulling back U.S. marketing, with the finance chief warning of another quarter of subscriber headwinds [2]. For a subscription business, a shrinking subscriber base is the one number you cannot explain away. Third, the guidance cut: Hims lowered its full-year adjusted-EBITDA outlook to roughly $257–$277 million, from $275–$325 million — its third reduction to that profit target this year — and guided fourth-quarter revenue to about $875–$895 million, well short of the roughly $954 million the Street had modeled [2].

Put together, the quarter told a coherent and unwelcome story: Hims is still growing fast, but the growth is coming from a lower-margin product mix while its highest-value metric — paying subscribers — is stalling. Management framed some of the profit pressure as timing (delayed recognition of weight-loss membership revenue) and investment (planned international pricing and marketing), which could prove temporary [2]. But the market, already wary of how volatile the weight-loss business makes this company, chose to reprice HIMS for the worse: from a high-margin subscription-telehealth story into a lower-margin seller of other companies' drugs with an uncertain subscriber trajectory. That the move was HIMS-specific was clear in the tape — telehealth peers barely budged, the broad market was roughly flat, and Eli Lilly, the branded-drug supplier, actually rose [5].

The valuation question

HIMS is no longer the richly valued growth story it was a year ago — the stock is down more than 50% over that span [1]. After the drop its market value is about $4.4 billion, or roughly 1.9 times trailing sales (and closer to 1.5 times forward sales given the growth), which is not demanding for a company still compounding revenue near 50% [3]. The catch is that the quality of that revenue has changed: a dollar of branded-drug sales is worth far less than a dollar of subscription revenue, so the same sales multiple implies lower profits than it used to. On earnings there is nothing to value — HIMS is loss-making on a trailing GAAP basis — though its adjusted EBITDA is positive and it generates positive operating cash flow, so this is not a solvency question, it is a margin-and-growth-quality question [3]. One more feature shapes the stock's behavior: HIMS is heavily shorted, with short interest around a quarter of its tradable shares, which is why it can lurch 8% higher on a drug deal one day and 18% lower on an earnings miss the next [1]. The valuation looks reasonable on sales, but only if margins and subscribers stabilize — the very things that just deteriorated.

Why it matters

Hims & Hers is the clearest public test of whether a consumer-health platform can turn the weight-loss-drug boom into durable profit. The GLP-1 wave handed HIMS enormous growth, but this quarter exposed the trap: as the business shifts from high-margin compounded drugs and subscriptions toward reselling branded medications, revenue can keep climbing while profitability goes the other way. The episode is a lesson in revenue quality — the market cares not just how fast a company grows but how much of each dollar it keeps, and a 49% revenue gain was worthless to investors once it came with a 17-point margin cut and a profit warning. The read-through was contained to HIMS: telehealth peers were roughly flat and Eli Lilly, whose drugs HIMS now resells, rose, underscoring that the pain sits specifically with the reseller, not the sector or the drug maker [5]. The resolution will not come from the next revenue headline but from the margin and subscriber lines: if Hims can use low-margin weight-loss drugs to acquire customers and then migrate them to higher-margin services, today looks like a painful transition; if margins stay compressed and subscribers keep slipping, the market will keep treating it as a lower-quality business than it once was.

The move, in one cross-section

The same-session tape shows a clean company-specific drop on a roughly flat day [5]:

HIMS down about 18% while its peers and the market were roughly flat — and Eli Lilly, the branded-drug supplier, was higher — is the signature of a company-specific catalyst: its own results, not a sector move [5].

What the Street thinks

Wall Street was already lukewarm, and the quarter cooled it further. The consensus rating is a Hold, not a Buy — unusual for a fast grower — from about 15 analysts, with an average 12-month target near $29, inside a wide range from about $23 to $42 [6]. Crucially, brokers moved on the print: several cut their targets into the mid-$20s the same day — for example to about $24–$25 — reflecting the margin and subscriber concerns, even as those targets still sit above the post-drop price [6]. That combination — a Hold consensus, freshly cut targets, but targets still above the price — captures the ambivalence: analysts see value in the growth and cash generation but are no longer willing to pay up for a business whose margins just deteriorated and whose subscriber trend turned negative. Unlike a high-conviction stock bought on every dip, HIMS is now a show-me story even to the Street [6].

What to watch

• Gross margin. Whether the slide to 57% stabilizes or keeps falling as the branded weight-loss mix grows — the single most important number next quarter [2].
• Subscribers. Whether the sequential decline reverses or the flagged "additional quarter of headwinds" turns into a trend [2].
• Cross-sell. Whether Hims can migrate weight-loss customers to higher-margin services, the key to making the GLP-1 strategy profitable rather than dilutive to margins [2].
• Guidance stability. Whether the EBITDA outlook holds after three cuts this year, or is reduced again. Moves are tracked on the Hims & Hers stock page [6].

Illustrative scenario sensitivity

Because the drop is a reaction to margin and subscriber quality rather than the growth rate, the scenarios below are anchored to how gross margin and the subscriber base evolve through the weight-loss-drug transition rather than to a single valuation [6]. They are a descriptive, author-weighted exercise over roughly the coming six-to-twelve months as those trends clarify — not a forecast, target, recommendation, or trading advice — with subjective weights that sum to 100%.

Weighting those (0.25 × $26 + 0.45 × $19 + 0.30 × $14) gives an author-weighted reference value near $19 — an illustrative, probability-weighted scenario output mechanically derived from the weights above, and not a price target, fair-value estimate, or prediction — essentially in line with Tuesday's ~$18.76 intraday price [1][6]. The near-identity reflects a genuinely balanced but wide-dispersion setup: a fast-growing, cash-generative platform trading cheaply on sales, offset by a real, unresolved question about whether the weight-loss-drug shift has permanently lowered its margins and stalled its subscriber growth. This is a scenario exercise and descriptive analysis of a news-driven move, not investment advice.

Hims & Hers data snapshot — November 10, 2026